Proceeding with a Phase 2b for Prurisol, imo, is the right thing to do. I'm a bit disappointed that it took so long to announce the plan but am happy now that it's moving forward. Starting a Phase 3 after the Phase 2 (and clearly without dose optimization) might sound good to some but it's expensive and it wouldn't allow for the best chance for success. Phase 2b will be fast and relatively inexpensive and will better demonstrate Prurisol's potential. Also, Cellceutix greatly improves their negotiating position while big pharma reduces risk for doing a good-sized deal.
I hope Prurisol remains in the discussion for mild psoriasis. It's a huge market and it's arguable that Prurisol could be huge for rapid clinical improvement and symptomatic relief. These were not effectively addressed in the Phase 2 trial.
Just a quick note on Brilacidin- I do believe the company could carve out smaller deals for different formulations. B-OM could be licensed after the Phase 2 wthout compromising the potential for the platform. Same for otic and opthalmic indications. In my mind, Brilacidin is not all or none for licensing.
Good luck to longs.
News 
Market Data 
Discover 
AI
